High nuclear grade and negative estrogen receptor are significant risk factors for recurrence in DCIS

Eur J Surg Oncol. 2004 Apr;30(3):243-7. doi: 10.1016/j.ejso.2003.11.004.


Introduction: Recommendations for adjuvant treatment of DCIS after breast conservation are controversial. We tried to identify further risk factors in a retrospective study of our own practice.

Patients and methods: Three hundred and thirty-two patients treated by breast conservation between 1978 and 2001 at the Department of General Surgery, University of Vienna were analysed. Tumour size, nuclear grade, hormone receptors, p53, her-2/neu, multifocality, microinvasion and post-operative therapy (irradiation, tamoxifen or combination) were analysed for their influence on breast recurrence.

Results: Overall recurrence rate was 6.1% (8/132). For patients with DCIS showing high nuclear grade or negative estrogen receptor the risk for development of ipsilateral breast recurrence is significantly higher. Newer factors like p53 and her-2/neu do not have any prognostic significance. No recurrence was observed in patients treated by post-operative irradiation and tamoxifen.

Conclusion: Nuclear grade remains the most significant factor for breast recurrence after DCIS. Hormone receptor status identifies a subset of patients with more favourable prognosis.

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / physiopathology
  • Breast Neoplasms / therapy
  • Carcinoma, Intraductal, Noninfiltrating / pathology*
  • Carcinoma, Intraductal, Noninfiltrating / physiopathology
  • Carcinoma, Intraductal, Noninfiltrating / therapy
  • Combined Modality Therapy
  • Female
  • Humans
  • Mastectomy, Segmental
  • Middle Aged
  • Neoplasm Recurrence, Local*
  • Radiotherapy, Adjuvant / methods
  • Receptors, Estrogen / physiology*
  • Retrospective Studies
  • Risk Factors
  • Tamoxifen / therapeutic use
  • Treatment Outcome


  • Antineoplastic Agents, Hormonal
  • Receptors, Estrogen
  • Tamoxifen